The FDA has cleared PTC Therapeutics’ gene therapy for AADC deficiency, an ultra-rare disease that impacts the ...
The amylin field is heating up ahead of Novo Nordisk's much-anticipated CagriSema readout later this year. On Wednesday, ...
The GAO report highlights FDA's drug inspection program challenges, including 36% fewer inspections in 2023 compared to 2019 ...
Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its spinouts Apriori ...
A lot of Amgen's future rides on its experimental obesity medicine MariTide. At least in the minds of investors. Ahead of the ...
Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in ...
Forward Health, a San Francisco-based primary care startup offering $150 monthly subscription services through ...
Johnson & Johnson is suing the federal government over HRSA's rejection of its proposed 340B drug discount model for Xarelto ...
BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...
Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
Novartis will pay $150 million upfront to Schrödinger, in a pact announced Tuesday to work together on several preclinical ...